Myocardial Perfusion Imaging

• US 20080267861A1
• Filed: 01/03/2008
• Published: 10/30/2008
• Est. Priority Date: 01/03/2007
• Status: Abandoned Application

• Current Assignee: Gilead Sciences Inc.
• Original Assignee: Gilead Palo Alto Incorporated (Gilead Sciences Inc.)
• Inventors: Lieu, Hsiao D., Thomas, Gregory
• Application Number:
  US11/969,047
• Publication Number:
  US 20080267861A1
• Time in Patent Office: Days
• US Class Current: 424/1.11
• CPC Class Codes: A61B 6/481 involving the use of contrast agents
• CPC Class Codes: A61B 6/507 for determination of haemodynamic parameters, e.g. perfusion CT
• CPC Class Codes: A61K 31/7076 containing purines, e.g. adenosine, adenylic acid

Abstract

This invention relates to methods for performing myocardial perfusion imaging for diagnosing and characterizing coronary artery disease using an intravenous (IV) bolus injection of regadenoson while the patient is undergoing sub-maximal exercise.

Claims

1. A method of diagnosing myocardial dysfunction during vasodilator induced myocardial stress perfusion imaging in a human patient, comprising administering at least 10 μ

g of at least one partial A_2A adenosine receptor agonist to the patient while the patient is undergoing sub-maximal exercise.

2. The method of claim 1, wherein no more than about 1000 μ

g of the partial A_2A adenosine receptor agonist is administered to the patient.

3. The method of claim 1, wherein the amount of the partial A_2A adenosine receptor agonist administered is greater than about 600 μ

g.

4. The method of claim 1, wherein the amount of the partial A_2A adenosine receptor agonist administered is greater than about 100 μ

g.

5. The method of claim 1, wherein the amount of the partial A_2A adenosine receptor agonist administered ranges from about 10 to about 600 μ

g.

6. The method of claim 5, wherein the A_2A adenosine receptor is administered in a single dose.

7. The method of claim 6, wherein the partial A_2A adenosine receptor agonist is administered by iv bolus.

8. The method of claim 6, the partial A_2A adenosine receptor agonist is administered in less than about 10 seconds.

9. The method of claim 6, wherein the amount of the partial A_2A adenosine receptor agonist administered is greater than about 500 μ

g.

10. The method of claim 6, wherein the partial A_2A adenosine receptor agonist is administered in an amount ranging from about 100 μ

g to about 500 μ

g.

11. The method of claim 1, wherein the partial A_2A adenosine receptor agonist is selected from the group consisting of CVT-3033, Regadenoson, and combinations thereof.

12. A method of diagnosing myocardial dysfunction during vasodilator induced myocardial stress perfusion imaging in a human patient, comprising administering a radionuclide and a partial A_2A receptor agonist in an amount ranging from about 10 to about 600 μ

g while the patient is undergoing sub-maximal exercise, wherein the myocardium is examined for areas of insufficient blood flow following administration of the radionuclide and the partial A_2A receptor agonist.

13. The method of claim 12, wherein the myocardium examination begins within about 1 minute from the time the partial A_2A adenosine receptor agonist is administered.

14. The method of claim 12, wherein the administration of the partial A_2A adenosine receptor agonist causes at least a 2.5 fold increase in coronary blood flow.

15. The method of claim 14, wherein the at least a 2.5 fold increase in coronary blood flow that is achieved within about 1 minute from the administration of the partial A_2A adenosine receptor agonist.

16. The method of claim 12, wherein the radionuclide and the partial A_2A adenosine receptor agonist are administered separately.

17. The method of claim 12, wherein the radionuclide and the partial A_2A adenosine receptor agonist are administered simultaneously.

18. The method of claim 14, wherein the at least a 2.5 fold increase in coronary blood flow is less than about 5 minutes in duration.

19. The method of claim 18, wherein the at least a 2.5 fold increase in coronary blood flow is less than about 3 minutes in duration.

20. A method of diagnosing myocardial dysfunction during vasodilator induced myocardial stress perfusion imaging in a human patient, comprising administering Regadenoson in an amount ranging from about 10 to about 600 μ

g in a single iv bolus while the patient is undergoing sub-maximal exercise.

21. A method of diagnosing myocardial dysfunction during vasodilator induced myocardial stress perfusion imaging in a human patient, comprising administering Regadenoson in an amount ranging from about 100 to about 500 μ

g in a single iv bolus while the patient is undergoing sub-maximal exercise.